PSI is a non-profit organisation formed in 1977 which provides a forum for regular discussion of statistics and issues relating to the practice of statistics in the pharmaceutical industry, as well as promoting good statistical practice within the industry.

Why join PSI

We provide...

opportunities for our members to network, develop themselves and shape the industry

We are...

run by our membership through a network of committees and special interest groups

We promote...

best statistical practice to our members and promote the value of statistics to the external world

Statisticians in the Pharmaceutical Industry
Executive Office: Durford Mill, Petersfield, Hampshire, GU31 5AZ e: t: +44 (0)1730 715 235 

EventsFuture Events

  • PSI Conference 2019 - Dates: 02 – 05 Jun, 2019

    PSI are pleased to announce that the countdown to the 2019 Conference has begun! The theme for the conference is “Data Driven Decision Making in Medical Research”. The 2019 PSI Conference will take place at the Queen Elizabeth II Centre (QEII), London, from 2nd to 5th June 2019.
  • Statistical Issues in Regulatory Submissions: Learning from the MHRA experience. - Dates: 10 Jun, 2019

    Based on the MHRA experience from hundreds of scientific advice meetings with industry and contributions to CHMP scientific advice, this one-day course will provide valuable insights to the most talked about methodological challenges facing applicants.
  • PSI Toxicology SIG Webinar "Pig-A Assay": - Dates: 18 – 18 Jun, 2019

    The in vivo Pig-a gene mutation assay is based on the endogenous X-linked Pig-a gene (phosphatidylinositol N-acetylglucosaminyltransferase, subunit A).
  • PSI One day Scientific meeting, South West: Designing and Analysing Adaptive Trial Design Studies - Dates: 24 – 24 Jun, 2019

    During this meeting we will hear about adaptive sample allocation for phase II/III designs, a new CONSORT extension reporting guideline for adaptive designs, regulatory aspects and case studies.
  • Introduction to Bayesian Statistics - Dates: 25 – 26 Jun, 2019

    The course will focus on the practical implementation of the background and practicalities of Bayesian design, analysis and reporting and will not go into deep statistical methodology or software coding. Examples and practical exercises are used throughout to aid understanding and interaction. References will be to give the attendee links to the statistical formulae and other reading.
  • PSI Webinar: Adaptive design: updated draft FDA guidance and its implications - Dates: 04 – 04 Jul, 2019

    In September 2018 the FDA published a guidance on adaptive design for clinical trials of drugs and biologics, updating (not finalizing) its initial draft from February 2010. The main focus of the webinar will be to provide an overview of its main contents, which will be presented by Jürgen Hummel (PPD). In addition, Kaspar Rufibach (Roche) will introduce an open-source statistical software for adaptive designs, RPACT (an R package that enables the design and analysis of confirmatory adaptive clinical trials). Kit Roes will also comment on the guidance from a European Regulatory perspective, which will be followed by a brief panel discussion.
  • PSI One day Scientific meeting: The analysis and reporting of PROs in Clinical Trials - Dates: 17 – 17 Jul, 2019

    The PSI Scientific Committee have put together this one day meeting to provide statisticians with introductions to PROs, how to include them in clinical trials, considerations about missing data, appropriate statistical methods to analyse and interpret the data and the perspective of an IQWiG assessor.
  • Introduction To Industry Training Course 2019 - Dates: 01 Oct, 2019

    The ITIT course will take 25 delegates new to the industry on a complete drug development experience from discovery to marketing. They will visit 6 companies from October 2019 to July 2020 to learn about 6 topics from experts in their field. The ITIT course will have 3 sessions in continental Europe and 3 sessions in the UK. It promises to be a truly memorable course.